Quick Answer
Esperion Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $167.85 million for the year ending 2025.
- Esperion Therapeutics, Inc. showed an increase of +16.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: $2.05 million | Q3 2012: $3.17 million | Q1 2013: $3.89 million | Q2 2013: $16.63 million | Q3 2013: $71.90 million | Q1 2014: $48.64 million | Q2 2014: $47.94 million | Q3 2014: $40.23 million | Q1 2015: $208.64 million | Q2 2015: $129.79 million | Q3 2015: $80.82 million | Q1 2016: $37.21 million | Q2 2016: $48.77 million | Q3 2016: $47.14 million | Q4 2016: $38.17 million | Q1 2017: $19.87 million | Q2 2017: $20.37 million | Q3 2017: $21.02 million | Q1 2018: $30.82 million | Q2 2018: $24.38 million | Q3 2018: $26.76 million | Q4 2018: $36.97 million | Q1 2019: $174.84 million | Q2 2019: $274.34 million | Q3 2019: $211.98 million | Q4 2019: $166.13 million | Q1 2020: $149.39 million | Q2 2020: $298.49 million | Q3 2020: $215.75 million | Q4 2020: $304.96 million | Q1 2021: $217.94 million | Q2 2021: $219.19 million | Q3 2021: $103.67 million | Q4 2021: $208.89 million | Q1 2022: $150.36 million | Q2 2022: $122.94 million | Q3 2022: $159.40 million | Q1 2023: $144.91 million | Q2 2023: $138.47 million | Q3 2023: $114.83 million | Q1 2024: $226.61 million | Q2 2024: $189.30 million | Q3 2024: $144.72 million | Q1 2025: $114.63 million | Q2 2025: $86.06 million | Q3 2025: $92.45 million.
- Over the full 16 years of available data (2010 to 2025), Esperion Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 4,815.3%.
- Historical annual values: Fiscal year 2025: $167.85 million | Fiscal year 2024: $144.76 million | Fiscal year 2023: $82.25 million | Fiscal year 2022: $124.78 million | Fiscal year 2021: $208.89 million | Fiscal year 2020: $304.96 million | Fiscal year 2019: $166.13 million | Fiscal year 2018: $36.97 million | Fiscal year 2017: $34.47 million | Fiscal year 2016: $38.17 million | Fiscal year 2015: $77.34 million | Fiscal year 2014: $85.04 million | Fiscal year 2013: $56.54 million | Fiscal year 2012: $6.51 million | Fiscal year 2011: $1.57 million | Fiscal year 2010: $3.41 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: